Aarti Pharmalabs Ltd vs Glaxosmithkline Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Aarti Pharmalabs Ltd is ₹ 788.5 as of 06 May 15:30 . The P/E Ratio of Aarti Pharmalabs Ltd changed from 12.9 on March 2023 to 24.9 on March 2025 . This represents a CAGR of 24.51% over 3 yearsThe P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 years The Market Cap of Aarti Pharmalabs Ltd changed from ₹ 2489 crore on March 2023 to ₹ 6784 crore on March 2025 . This represents a CAGR of 39.69% over 3 yearsThe Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 years The revenue of Aarti Pharmalabs Ltd for the Dec '25 is ₹ 436.83 crore as compare to the Sep '25 revenue of ₹ 418.39 crore. This represent the growth of 4.41% The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The ebitda of Aarti Pharmalabs Ltd for the Dec '25 is ₹ 104.07 crore as compare to the Sep '25 ebitda of ₹ 74.13 crore. This represent the growth of 40.39% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The net profit of Aarti Pharmalabs Ltd changed from ₹ 55.45 crore to ₹ 47.96 crore over 7 quarters. This represents a CAGR of -7.96% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The Dividend Payout of Aarti Pharmalabs Ltd changed from 10.55 % on March 2023 to 17.61 % on March 2025 . This represents a CAGR of 18.62% over 3 yearsThe Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 years .

About Aarti Pharmalabs Ltd

Aarti Pharmalabs Limited was initially incorporated as 'Aarti Organics Limited' in 2019.
The name of the Company was changed to Aarti Pharmachem Limited from Aarti Organics Limited' in July, 2021 and to Aarti Pharmalabs Limited in 2022.
Company is a manufacturer of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine derivatives situated in India.
It specialise in developing and manufacturing Highly Potent Active Pharmaceutical Ingredients (HPAPIs) critical for various therapeutic segments such as Anti-cancer, Anti-Asthma, Anti-Hypertensive etc. In 2001, the Company commissioned first API manufacturing Unit in Dombivali (Unit 1) and started Xanthine Unit; further it commissioned first API manufacturing Unit 4 in Tarapur for Regulated Markets in 2005; commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tonnes (MT) per month in 2016.

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

FAQs for the comparison of Aarti Pharmalabs Ltd and Glaxosmithkline Pharmaceuticals Ltd

Which company has a larger market capitalization, Aarti Pharmalabs Ltd or Glaxosmithkline Pharmaceuticals Ltd?

Market cap of Aarti Pharmalabs Ltd is 7,148 Cr while Market cap of Glaxosmithkline Pharmaceuticals Ltd is 41,069 Cr

What are the key factors driving the stock performance of Aarti Pharmalabs Ltd and Glaxosmithkline Pharmaceuticals Ltd?

The stock performance of Aarti Pharmalabs Ltd and Glaxosmithkline Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aarti Pharmalabs Ltd and Glaxosmithkline Pharmaceuticals Ltd?

As of May 6, 2026, the Aarti Pharmalabs Ltd stock price is INR ₹788.5. On the other hand, Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2424.3.

How do dividend payouts of Aarti Pharmalabs Ltd and Glaxosmithkline Pharmaceuticals Ltd compare?

To compare the dividend payouts of Aarti Pharmalabs Ltd and Glaxosmithkline Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.